Maravai Q4 revenue $228M, up 132% YoY; net income $127M; 2022 guidance raised to $920-960M

MARAVAI LIFESCIENCES HOLDINGS, INC.

2021-FY EPS reported $1.56 revenue$799,240,000

Q4 revenue $228.4M (+132% YoY); net income $127.1M (+778% YoY).
FY2021 revenue $799.2M (+181% YoY); net income $469.3M; adjusted EBITDA $582.8M.
Nucleic Acid Production segment Q4 revenue $212.5M (+173% YoY) driven by CleanCap demand for mRNA vaccines.
2022 revenue guidance raised to $920M-$960M, implying 15-20% growth over 2021 record.
Completed debt repricing saving ~$6.8M annually in interest; acquired MyChem for ultra-pure nucleotides.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.